Detalles de la búsqueda
1.
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.
Clin Diabetes Endocrinol
; 10(1): 9, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38659082
2.
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Aliment Pharmacol Ther
; 58(9): 888-902, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37642160
3.
A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
JHEP Rep
; 5(10): 100845, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37663119
4.
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
Biomedicines
; 10(3)2022 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35327501
5.
Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs.
J Clin Exp Hepatol
; 12(2): 293-305, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35535064
6.
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
Aliment Pharmacol Ther
; 54(7): 952-966, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34398492
Resultados
1 -
6
de 6
1
Próxima >
>>